表紙
市場調査レポート

EpiCast Report:糖尿病性神経障害の疫学的予測

EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 291029
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
EpiCast Report:糖尿病性神経障害の疫学的予測 EpiCast Report: Diabetic Neuropathy - Epidemiology Forecast to 2022
出版日: 2013年11月30日 ページ情報: 英文 45 Pages
概要

世界の主要7ヶ国における糖尿病性神経障害の有病者数は、2012年には13,842,033人、2022年には19,783,289人に達すると予想されています。その内、米国が全体の45%と最大の有病者数を抱えています。有病者数の増加の要因として、人口構造の変化や、糖尿病と診断された有病者数の増加などが挙げられます。

当レポートでは、世界の主要7ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国・日本)における糖尿病性神経障害の発症状況や今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 米国
    • 欧州主要5ヶ国
    • 日本
  • 糖尿病性神経障害の疫学的予測(今後11年間分)
    • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法:診断された糖尿病の有病者数
    • 予測の前提条件と手法:糖尿病性神経障害
  • 糖尿病性神経障害の疫学予測(今後11年間分)
    • 糖尿病性神経障害
    • 糖尿病性神経障害の有病者数:年齢別
    • 糖尿病性神経障害の有病者数:男女別
    • 糖尿病性神経障害の有病者数:高血圧を併発した症例数
  • 議論
    • 疫学的な動向に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER049

Diabetic neuropathy affects an estimated 50% of patients with diabetes and is one of the leading causes of morbidity in diabetic patients, often leading to foot ulcerations or amputation. Diabetic neuropathy is clinically defined as "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes" (Argoff et al., 2006; Boulton et al., 1998).

According to the epidemiologic literature, poor glycemic control, age, duration of diabetes, and obesity are risk factors for diabetic neuropathy (Abbott et al., 2011; Adler et al., 1997; Argoff et al., 2006; Tesfaye and Selvarajah, 2012). However, diabetic neuropathy is considered to be part of the natural progression of diabetes as a microvascular complication of the disease.

GlobalData epidemiologists forecast that the total prevalent cases of diabetic neuropathy in the diagnosed diabetic population in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) will increase from 13,842,033 cases in 2012 to 19,783,289 cases in 2022 at an Annual Growth Rate (AGR) of 4.29%. Throughout the forecast period, the US will have the highest number of total prevalent diabetic neuropathy cases in the diagnosed diabetic population, with approximately 45% of the cases. The increase in the number of total prevalent cases of diabetic neuropathy in the 7MM is the result of changing population demographics and GlobalData's predicted increase in the diagnosed prevalent cases of diabetes in the 7MM.

Scope

  • The diabetic neuropathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic neuropathy in the seven major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast of the total prevalent cases of diabetic neuropathy in the diagnosed diabetic population segmented by age, (adults over the age of 40 years), sex, and the proportion of comorbid hypertension prevalent case in these markets.
  • The diabetic neuropathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global DFU market.
  • Quantify patient populations in the global diabetic neuropathy market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic neuropathy therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Epidemiological Forecast for Diabetic Neuropathy (2012-2022)
    • 3.4.1. Forecast Methodology
    • 3.4.2. Sources Used
    • 3.4.3. Sources Not Used
    • 3.4.4. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of Diabetes
    • 3.4.5. Forecast Assumptions and Methods - Diabetic Neuropathy
  • 3.5. Epidemiology Forecast for Diabetic Neuropathy (2012-2022)
    • 3.5.1. Diabetic Neuropathy
    • 3.5.2. Total Prevalent Cases of Diabetic Neuropathy by Age
    • 3.5.3. Total Prevalent Cases of Diabetic Neuropathy by Sex
    • 3.5.4. Total Prevalent Cases of Diabetic Neuropathy, Comorbid Hypertension
  • 3.6. Discussion
    • 3.6.1. Conclusions on Epidemiological Trends
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Health Policy
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Neuropathic Pain Descriptor Terms
  • Table 2: 7MM, Sources of Diabetic Neuropathy Total Prevalence Data
  • Table 3: 7MM, Excluded Sources of Diabetic Neuropathy Total Prevalence Data
  • Table 4: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ≥ 40 Years, N, 2012-2022
  • Table 5: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, Row (%), 2012
  • Table 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ≥ 40 Years, N, Row (%), 2012

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ≥ 40 Years, N, 2012-2022
  • Figure 2: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, 2012
  • Figure 3: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ≥ 40 Years, N, 2012
  • Figure 4: 7MM, Comorbid Hypertension in Diabetic Neuropathy Cases (N), Both Sexes, Ages 40+, 2012
Back to Top